Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Niharika Dixit
Headshot of Niharika Dixit
Niharika Dixit

Description

Summary

This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.

Official Title

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Details

Keywords

Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm, Neoplasms, Megestrol, Megestrol Acetate, Olanzapine

Eligibility

Locations

Lead Scientist at UCSF

  • Niharika Dixit
    Professor, Medicine, School of Medicine. Authored (or co-authored) 56 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Alliance for Clinical Trials in Oncology
ID
NCT04939090
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 360 study participants
Last Updated